Shoichi Ohkubo

This inventor holds 9 USPTO granted patents. Top assignees: Takeda Chemical Industries, Inc., Takeda Pharmaceutical Company Limited. Active years: 1996-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shoichi Ohkubo. Retrieved from https://idiyas.com/inventor/shoichi-ohkubo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 66.7

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 81(Granted Patents)

Location History:

Tsukuba Ibaraki, JP (1998)
Tsukuba, JP (2000 - 2002)
Ibaraki, JP (1996 - 2007)
Osaka, JP (2011)

Company Filing History:

6 out of 1,858

Takeda Chemical Industries, Inc.

patents

3 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 1996-2011

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7943137 - FPRL1 ligands and use thereof (2011-05-17),

2. 7892755 - Screening method (2011-02-22),

3. 7214495 - Screening method (2007-05-08),

4. 6797483 - Polypeptide and DNA thereof (2004-09-28),

5. 6365725 - DNA coding for a human vasoconstrictive peptide and use thereof (2002-04-02),

6. 6117645 - Human LH-RH receptor expression cells and use thereof (2000-09-12),

7. 5756344 - DNA coding for a human vasoconstrictive peptide and use thereof (1998-05-26),

8. 5677184 - CHO cells that express human LH-RH receptor (1997-10-14),

9. 5521069 - Genomic DNA exons having exons encoding human pituitary adenylate (1996-05-28),

Title: The Innovations of Shoichi Ohkubo

Introduction

Shoichi Ohkubo is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of biochemistry and pharmacology, holding a total of 9 patents. His work primarily focuses on the development of compounds that can be used in the treatment of various medical conditions.

Latest Patents

One of his latest patents involves FPRL1 ligands and their applications. This invention utilizes FPRL1 ligands that share a similar amino acid sequence with specific sequences represented by SEQ ID NO: 1, SEQ ID NO: 17, or SEQ ID NO: 21. By employing these ligands, an efficient screening process for FPRL1 agonists or antagonists can be conducted. Another significant patent details a method for screening compounds that alter the binding properties of proteins with similar amino acid sequences. This method is particularly useful for identifying agents that can prevent or treat digestive tract disorders, cancer, immune disorders, type II diabetes mellitus, and obesity.

Career Highlights

Throughout his career, Shoichi Ohkubo has worked with prominent companies in the pharmaceutical industry, including Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.

Collaborations

He has collaborated with esteemed colleagues such as Haruo Onda and Shuji Hinuma, further enhancing the impact of his work in the scientific community.

Conclusion

Shoichi Ohkubo's innovative contributions to biochemistry and pharmacology have led to significant advancements in medical treatments. His patents reflect a commitment to improving health outcomes through scientific research and collaboration.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]